Federal Crackdown on Medicare Fraud
The U.S. Department of Justice (DOJ) announced a sweeping series of criminal charges this week targeting a widespread Medicare fraud scheme involving the overutilization of expensive skin substitutes. Federal prosecutors allege that health care providers and medical supply companies billed the government nearly $15 billion in 2025 for wound care treatments that were either medically unnecessary or never performed, marking one of the largest health care fraud enforcement actions in recent history.
Skin substitutes, often derived from human or animal tissue, are intended for complex, non-healing wounds such as diabetic ulcers. While these products are clinically effective in specific cases, federal investigators argue that a coordinated network of clinics has exploited billing loopholes to inflate costs, often applying products far beyond standard medical necessity to maximize reimbursements.
The Context of Wound Care Billing
The rise in skin substitute spending has become a major concern for the Centers for Medicare & Medicaid Services (CMS). Over the past five years, the market for these biological products has surged, with total Medicare expenditures growing at a rate that significantly outpaced the actual growth of the patient population requiring advanced wound care.
Industry analysts point to a lack of standardization in coding for these products as a primary driver of the abuse. Because many skin substitutes are classified under a broad range of billing codes, providers have been able to upcode cheaper products to those with higher reimbursement rates, creating a lucrative incentive structure for clinics that prioritize profit over clinical outcomes.
Analyzing the Scope of the Scheme
The DOJ’s investigation spans multiple states, targeting clinics that allegedly recruited patients for unnecessary wound care procedures. According to court filings, investigators tracked patterns of
